Rx0000137 |
Celgene |
03/31/2019 |
59572063255 |
Apremilast 10 & 20 & 30 MG Tablet Therapy Pack 55 EA UU |
01/03/2019 |
114.91 |
3398.00 |
05/29/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Otezla were $1.275 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572063106 |
Apremilast 30 MG Tablet 60 EA |
01/03/2019 |
114.91 |
3398.00 |
05/29/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Otezla were $1.275 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572041000 |
Lenalidomide 10 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572041028 |
Lenalidomide 10 MG Capsule 28 EA |
01/03/2019 |
681.57 |
20154.94 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572041500 |
Lenalidomide 15 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572041521 |
Lenalidomide 15 MG Capsule 21 EA |
01/03/2019 |
511.18 |
15116.23 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572040200 |
Lenalidomide 2.5 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572040228 |
Lenalidomide 2.5 MG Capsule 28 EA |
01/03/2019 |
681.57 |
20154.94 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572042000 |
Lenalidomide 20 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572042021 |
Lenalidomide 20 MG Capsule 21 EA |
01/03/2019 |
511.18 |
15116.23 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572042500 |
Lenalidomide 25 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572042521 |
Lenalidomide 25 MG Capsule 21 EA |
01/03/2019 |
511.18 |
15116.23 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572040500 |
Lenalidomide 5 MG Capsule 100 EA |
01/03/2019 |
2434.17 |
71981.98 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572040528 |
Lenalidomide 5 MG Capsule 28 EA |
01/03/2019 |
681.57 |
20154.94 |
03/08/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Revlimid were $6.469 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
68817013450 |
Paclitaxel Protein-Bound Particles 100 MG Suspension Reconstituted 1 EA UD |
01/03/2019 |
46.60 |
1378.01 |
01/12/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Abraxane was $663 million. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050100 |
Pomalidomide 1 MG Capsule 100 EA |
01/03/2019 |
2770.79 |
81936.32 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050121 |
Pomalidomide 1 MG Capsule 21 EA |
01/03/2019 |
581.87 |
17206.63 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050200 |
Pomalidomide 2 MG Capsule 100 EA |
01/03/2019 |
2770.79 |
81936.32 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050221 |
Pomalidomide 2 MG Capsule 21 EA |
01/03/2019 |
581.87 |
17206.63 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050300 |
Pomalidomide 3 MG Capsule 100 EA |
01/03/2019 |
2770.79 |
81936.32 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050321 |
Pomalidomide 3 MG Capsule 21 EA |
01/03/2019 |
581.87 |
17206.63 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050400 |
Pomalidomide 4 MG Capsule 100 EA |
01/03/2019 |
2770.79 |
81936.32 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000137 |
Celgene |
03/31/2019 |
59572050421 |
Pomalidomide 4 MG Capsule 21 EA |
01/03/2019 |
581.87 |
17206.63 |
06/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product.
In 2018, total U.S. sales for Pomalyst were $1.391 billion. |
Rx0000080 |
Cipla USA, Inc. |
06/30/2019 |
69097080540 |
AZACITIDINE FOR INJ 100MG/VIAL |
04/16/2019 |
105.00 |
210.00 |
None |
Non-innovator Multiple Source Drug |
27696 |
None |
This product was not launched into the market until after the WAC change on 4/16/2020. Therefore, there was no product sold into the market at the old WAC. The WAC change was a result of further market analysis prior to launch. |
None |
There was no significant change or improvement to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not Acquired |
Rx0000080 |
Cipla USA, Inc. |
03/31/2019 |
69097086283 |
Calcium Acetate Tablet |
03/04/2019 |
29.03 |
120.00 |
None |
Non-innovator Multiple Source Drug |
9394000 |
None |
Increase in API Cost |
None |
Increase in API Cost |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=27 |
None |
Rx0000146 |
Circassia Pharmaceuticals |
09/30/2019 |
72124000202 |
Tudorza Pressair Inhalation Powder 400mcg 30 actuations |
07/01/2019 |
84.12 |
260.00 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/17/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
175.88 |
170.75 |
2015 |
140.70 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue.
As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-39. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-02. |
Rx0000146 |
Circassia Pharmaceuticals |
09/30/2019 |
72124000201 |
Tudorza Pressair Inhalation Powder 400mcg 60 actuations |
07/01/2019 |
168.25 |
520.00 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/17/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
351.75 |
341.51 |
2015 |
281.40 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue.
As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01. |
Rx0000320 |
CMP Pharma |
12/31/2019 |
46287002004 |
CaroSpir spironolactone oral suspension 25mg/5ml 18ml |
10/01/2019 |
26.50 |
320.80 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000320 |
CMP Pharma |
12/31/2019 |
46287002001 |
CaroSpir spironolactone oral suspension 25mg/5ml 473ml |
10/01/2019 |
95.30 |
1154.80 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000320 |
CMP Pharma |
12/31/2019 |
46287000604 |
Sodium Polystyrene Suspension 120ml enema kit |
11/01/2019 |
38.30 |
78.80 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000320 |
CMP Pharma |
12/31/2019 |
46287000601 |
Sodium Polystyrene Suspension 473ml |
11/01/2019 |
64.60 |
132.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000320 |
CMP Pharma |
12/31/2019 |
46287000660 |
Sodium Polystyrene Suspension 60ml unit dose X 10 |
11/01/2019 |
85.40 |
175.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865024502 |
NUCYNTA ER-100MG-100 TABLET |
01/01/2019 |
75.26 |
760.20 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865025002 |
NUCYNTA ER-150MG-100 TABLET |
01/01/2019 |
97.10 |
980.79 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865026002 |
NUCYNTA ER-200MG-100 TABLET |
01/01/2019 |
123.26 |
1245.06 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865026501 |
NUCYNTA ER-250MG-100 TABLET |
01/01/2019 |
154.21 |
1557.70 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865024002 |
NUCYNTA ER-50MG-100 TABLET |
01/01/2019 |
40.69 |
411.05 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865023002 |
NUCYNTA IR-100MG-100 TABLET |
01/01/2019 |
98.07 |
990.64 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865021002 |
NUCYNTA IR-50MG-100 TABLET |
01/01/2019 |
62.98 |
636.15 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
69865022002 |
NUCYNTA IR-75MG-100 TABLET |
01/01/2019 |
73.58 |
743.28 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
24510011510 |
XTAMPZA ER-13.5MG-100 CAPSULES |
01/01/2019 |
59.09 |
655.98 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
24510012010 |
XTAMPZA ER-18MG-100 CAPSULES |
01/01/2019 |
74.94 |
831.89 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
24510013010 |
XTAMPZA ER-27MG-100 CAPSULES |
01/01/2019 |
104.25 |
1157.23 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
24510014010 |
XTAMPZA ER-36MG-100 CAPSULES |
01/01/2019 |
128.31 |
1424.38 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000200 |
Collegium Pharmaceuticals |
03/31/2019 |
24510011010 |
XTAMPZA ER-9MG-100 CAPSULES |
01/01/2019 |
40.15 |
445.70 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000154 |
Corcept Therapeutics Incorporated |
09/30/2019 |
76346007302 |
Korlym (mifepristone) 300mg Tablets 280-ct Bottles |
08/01/2019 |
11480.00 |
139720.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
The drug was developed by Corcept. |
Rx0000154 |
Corcept Therapeutics Incorporated |
09/30/2019 |
76346007301 |
Korlym (mifepristone) 300mg Tablets 28-ct Bottles |
08/01/2019 |
1148.00 |
13972.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
The drug was developed by Corcept. |
Rx0000184 |
Cosette Pharmaceuticals, Inc. |
12/31/2019 |
00713016612 |
MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg |
11/04/2019 |
70.23 |
140.46 |
None |
Single Source Drug |
None |
1 |
Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio. |
None |
None |
1 |
06/28/2019 |
Horizon Therapeutics PLC |
None |
1 |
None |
70.23 |
39.96 |
1983 |
0.01 |
None |
WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W. |
Rx0000181 |
Currax Pharmaceuticals LLC |
12/31/2019 |
42847085009 |
Treximet 9 tab/pk (sumatriptan/naproxen) 85 mg/500 mg |
10/25/2019 |
96.67 |
1062.90 |
04/02/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Pharmaceuticals |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not the price limited to this single NDC. |
967.23 |
880.09 |
2015 |
625.50 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Pharmaceuticals. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC maintains no liability for pricing and pricing history prior to April 30, 2019.
Since the acquisition was in bankruptcy, the asset purchase amount for the product is not reported nor public. |